Treatment of Concurrent Minimal Change Disease and Epstein Barr Virus-Driven Post-transplant Lymphoproliferative Disorder With Rituximab Following Hematopoietic Stem Cell Transplantation

Kidney Int Rep. 2020 Oct 17;6(1):224-227. doi: 10.1016/j.ekir.2020.10.012. eCollection 2021 Jan.

Authors

Louise Ainley¹, Steven Law², Lauren Heptinstall³, Manuel Rodriguez-Justo⁴, Kirsty Thomson¹, Ruth J Pepper⁵

Affiliations

¹ Department of Hematology, University College Hospital NHS Trust, London, UK.
² National Amyloidosis Centre, Division of Medicine, University College London, London, UK.
³ Department of Pathology, Royal Free Hospital, London, UK.
⁴ Department of Pathology, University College Hospital, London, UK.
⁵ UCL Department of Renal Medicine, Clinical Kidney Disease, Royal Free Hospital, London, UK.

No abstract available

Publication types

Case Reports